SUCCESSFUL COMPLETION OF PLANNED IDMC REVIEW OF ACTION3 PHASE 3 FSGS KIDNEY TRIAL
Posted: 20 November 2024 Dimerix Limited (ASX: DXB) a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, today confirmed that the Independent Data Monitoring Committee (IDMC) successfully concluded a fifth review of the ACTION3 phase 3 clinical…
ViiV HEALTHCARE ANNOUNCES DATA DEMONSTRATING DOVATO (DTG/3TC) IS HIGHLY EFFECTIVE IN TREATMENT-NAIVE PEOPLE WITH ADVANCED HIV
Posted: 20 November 2024 ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 48-week findings from the DOLCE study, sponsored by Fundación Huésped and the Bahiana Foundation of…
Psilocybin shows promise for treating obsessive compulsive disorder
Posted: 20 November 2024 A single dose may reduce compulsive behaviours in mice Research at The Florey suggests the psychedelic compound psilocybin has potential to treat obsessive-compulsive disorder (OCD) and related disorders. The study – led by Florey…
Establishing Genomics Australia
Posted: 20 November 2024 The Albanese Government is establishing a new national body to provide leadership, coordination and expertise so all Australians can reap the benefits of cutting-edge genomic research and technologies. Genomics Australia will help fight cancers,…
All in the blood: new way to detect drug resistance in ovarian cancer patients
Posted: 20 November 2024 WEHI researchers have found a new way to predict a subset of patients who are likely to become resistant to PARP inhibitors (PARPi), a key therapy used to treat ovarian and breast cancers in…
Visionary leaders to drive pioneering research centre
Posted: 20 November 2024 Two esteemed researchers have been appointed to lead the Colonial Foundation Diagnostics Centre, a landmark research centre working to enhance precision diagnosis for inflammatory diseases. The centre, co-led by WEHI and the Royal Melbourne Hospital…
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
Posted: 20 November 2024 Telix today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program will initially focus on…
Audit finds Australia’s health and medical researchers are passionate, diverse and highly mobile
Posted: 20 November 2024 We have undertaken a national audit of Australia’s health and medical research workforce. You can now read our findings and learn about opportunities to support our researchers into the future. We carried out the…
New digital project to reveal medical research career opportunities
Posted: 19 November 2024 To increase awareness of the breadth of career pathways available across the health and medical research sector, BioMelbourne Network is kicking-off a one-year project to develop a central portal containing a suite of workforce…
Celebrating leadership and breaking barriers: Women in Leadership Awards inspire
Posted: 19 November 2024 Resilience, adaptability and the courage to challenge the status quo were the defining themes of BioMelbourne Network’s recent Women in Leadership Awards Celebration, held at Allens’ offices on Melbourne’s Collins Street. Karen Parr, BioMelbourne…
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Posted: 14 November 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial…
Amplia enters into preclinical collaboration with Korean specialist drug screening company Next&Bio
Posted: 14 November 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that it has entered into a research collaboration with Korean preclinical drug screening company Next&Bio. A research collaboration agreement between the…
